TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05453318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment of cervical neoplasia by thermal ablation
Description: Women screened for cervical cancer by VIA presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
Study: NCT01682876

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MenACWY-CRM
Description: The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-CRM
Description: The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MenACWY-CRM
Description: The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-CRM
Description: The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm
Study: NCT02567331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive 1250 mg/m\^2 capecitabine administered twice daily as oral tablets for 14 days followed by a 7 day rest period for up to 6 treatment cycles.
Study: NCT01617343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hemifield eye patching (HEP) + optokinetic stimulation (OKS)
Description: Patients in this arm will wear standard spectacle frames containing noncorrective lenses to which right half-field patches are attached (hemifield eye patching, HEP). In case of patients already wearing prescribed glasses, the patches will be attached to their own glasses. The glasses will be worn all-day for the duration of the treatment phase (seven days) and only be removed for sleeping and face cleaning as well as for the duration of the daily OKS treatment sessions.~Furthermore these patients will receive daily sessions (20 minutes) of optokinetic stimulation (OKS). Therefore patients will be seated in front of a widescreen monitor, watching a black background with a pattern of various objects (size 1°), which coherently and continuously move to the left at a velocity of 10 °/s.
Study: NCT03797781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower limb immobilisation (leg brace) with varying levels of protein intake
Description: Single leg immobilisation via leg brace and crutches, the groups have different amounts of protein intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower limb immobilisation (leg brace) with varying levels of protein intake
Description: Single leg immobilisation via leg brace and crutches, the groups have different amounts of protein intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower limb immobilisation (leg brace) with varying levels of protein intake
Description: Single leg immobilisation via leg brace and crutches, the groups have different amounts of protein intake
Study: NCT01546311

Intervention type: DEVICE
Intervention: Pro Active Dynamic Accommodating Socket
Description: Socket with bladders that instantaneously adjusts to volume fluctuations in the residual limb
Study: NCT00423878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Continued treatment with the medication olanzapine for schizophrenia for up to 6 months in study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Continued treatment with the medication quetiapine for schizophrenia for up to 6 months in study
Study: NCT02509065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm for type 1 diabetes patients will deliver insulin and glucagon. The 100 mg/dl arm for type 2 diabetes patients will deliver just insulin. The 115 mg/dl arm will deliver insulin and glucagon. The 120 mg/dl arm will deliver just insulin. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl and 110 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm for type 1 diabetes patients will deliver insulin and glucagon. The 100 mg/dl arm for type 2 diabetes patients will deliver just insulin. The 115 mg/dl arm will deliver insulin and glucagon. The 120 mg/dl arm will deliver just insulin. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl and 110 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm for type 1 diabetes patients will deliver insulin and glucagon. The 100 mg/dl arm for type 2 diabetes patients will deliver just insulin. The 115 mg/dl arm will deliver insulin and glucagon. The 120 mg/dl arm will deliver just insulin. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl and 110 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participant cares for their diabetes according to their usual practice, with blinded CGM monitoring. No medication will be administered by the study in this intervention.
Study: NCT04682821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial intelligence assistant system
Description: The intervention is the use of the artificial intelligence assistant system in addition to the common training. The system is an non-invasive AI system which could help the endoscopists to diagnosis and monitor the blind spot during the gastroscope.
Study: NCT04480255

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: Standard of Care
Description: Those who are in Group 1 will receive the usual care which includes:~1. a welcome packet from the nursing staff~2. access to their infant's medical team including doctors and nurse~3. opportunities to ask any questions and understand the care their baby is receiving through participation in daily work rounds or through setting up family meetings with the medical team.
Study: NCT01390376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAAOI-1
Description: DAAOI-1 1g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAAOI-1
Description: DAAOI-1 2g

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: starch pill
Study: NCT04067310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spray skin protector
Description: Patients will use spray skin protector treatment from the randomization day until the last day of radiotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: moisturizer Dnativ Revita derm
Description: Patients will use conventional preventive treatment from the randomization day until the last day of radiotherapy.
Study: NCT01393652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05105679
Description: Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05105679
Description: Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05105679
Description: Subject will be randomized to a treatment sequence, and assigned to placebo, 2 separate single doses of PF-05105679 in the fasted state and to controlled-release Oxycodone 20 mg (positive control) , with at least one week wash-out between doses.
Study: NCT02928900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician training intervention
Description: This intervention is a clinician training using SP actors to improve communication and empathy skills of HIV care providers who serve HIV-positive adolescents and youth in Kenya.
Study: NCT04480255

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: NICU2HOME+ app
Description: In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 2 parents will be asked to download the NICU2HOME app.
Study: NCT00253747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osmotic-Release Methylphenidate
Description: OROS-MPH dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: OROS-MPH (placebo) dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
Study: NCT04263974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone Application
Description: Exercises and recommendations, based on current scientific evidence, and delivered through the app for Smartphone called CareHand. The intervention protocol is based on strengthening and stretching recommendations for rheumatoid arthritis and osteoarthritis in hands, transferred to an application format through explanatory videos together with tools to improve the autonomy, motivation and adherence of the patient
Study: NCT03844282

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical assessment (SCAT5)
Description: The SCAT5 is a standardized tool for evaluating sports-related concussions designed for use by physicians and licensed healthcare professionals in patients aged 13 years and above. It is a ten minute paper-based assessment which includes immediate and office/off-field assessments. SCAT5 incorporates the Maddocks' questions, Glasgow Coma Scale (GCS), cervical spine assessment and symptom evaluation, in addition to cognitive and neurological screening.
Study: NCT04263974

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventional approach provided by the Andalusian Public Health System in Primary Care settings. This approach consists of routine visits to the general practitioner specialist, and the delivery of an exercise sheet and recommendations. This general mobility and stretching worksheet contains detailed images, as well as a description of how to perform the exercises and the dose to be taken. While most exercises are intended for the wrist and hands, this sheet also includes basic exercises for the elbow joint.
Study: NCT01289769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine 0.7 microgram per kilogram in saline 20 ml given within 10 minutes before intubation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline 20 ml( the same volume as dexmedetomidine) giving within 10 minutes.
Study: NCT03844282

Intervention type: OTHER
Intervention: fMRI
Description: RESCUE-RACER participants will be invited to complete a functional MRI scan, whose 90-minute protocol may include: multi-parametric mapping (MPM), susceptibility weighted imaging (SWI), diffusion weighted imaging (DWI), proton spectroscopy and functional MRI (fMRI) with blood oxygenation-level dependent contrast (BOLD), completed at 7T (Tesla), or 3T if this is not possible.

Intervention type: OTHER
Intervention: fMRI
Description: RESCUE-RACER participants will be invited to complete a functional MRI scan, whose 90-minute protocol may include: multi-parametric mapping (MPM), susceptibility weighted imaging (SWI), diffusion weighted imaging (DWI), proton spectroscopy and functional MRI (fMRI) with blood oxygenation-level dependent contrast (BOLD), completed at 7T (Tesla), or 3T if this is not possible.
Study: NCT01439308

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SB-705498 placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB-705498
Description: 12mg intranasal SB-705498
Study: NCT01334658

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification cataract surgery
Description: A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..).
Study: NCT00313716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human erythropoietin, rhEpo
Description: The study design is 2x2 factorial with randomization to erythropoietin or placebo and to transfusion trigger 10 gm/dl or 7 g/dl. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (first 74 patients, Epo1 dosing regimen), and then the 24- and 48-hour doses were stopped for the remainder of the patients (remaining 126 patients, Epo2 dosing regimen).
Study: NCT00423878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Switching medication to aripiprazole for schizophrenia for up to 6 months in study
Study: NCT00313716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human erythropoietin, rhEpo
Description: The study design is 2x2 factorial with randomization to erythropoietin or placebo and to transfusion trigger 10 gm/dl or 7 g/dl. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (first 74 patients, Epo1 dosing regimen), and then the 24- and 48-hour doses were stopped for the remainder of the patients (remaining 126 patients, Epo2 dosing regimen).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human erythropoietin, rhEpo
Description: The study design is 2x2 factorial with randomization to erythropoietin or placebo and to transfusion trigger 10 gm/dl or 7 g/dl. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (first 74 patients, Epo1 dosing regimen), and then the 24- and 48-hour doses were stopped for the remainder of the patients (remaining 126 patients, Epo2 dosing regimen).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human erythropoietin, rhEpo
Description: The study design is 2x2 factorial with randomization to erythropoietin or placebo and to transfusion trigger 10 gm/dl or 7 g/dl. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (first 74 patients, Epo1 dosing regimen), and then the 24- and 48-hour doses were stopped for the remainder of the patients (remaining 126 patients, Epo2 dosing regimen).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study: NCT00122382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: abatacept 10 mg/kg IV monthly, methotrexate weekly, for 24 months
Study: NCT00313716

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study: NCT01560676

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HEALTH[e]TEEN
Description: 8 lessons over 6-8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HEALTH[e]TEEN + CST
Description: 12 lessons over 6-8 weeks
Study: NCT02979275

Intervention type: PROCEDURE
Intervention: Open heart surgery on cardiopulmonary bypass.
Description: Brain oximetry and tissue saturation will be measured during operation. NGAL, cystatin-C, and Acute Kidney Injury Network (AKIN) criteria of AKI will be assessed durin first post-op day.
Study: NCT04260360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension
Description: NanoDoce is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate docetaxel nanoparticles within a well-characterized particle-size distribution. Prior to administration, the NanoDoce powder in vial is suspended with a sterile solution of Polysorbate 80 (0.0075% - 0.0375% (w/w))/Ethanol (0.06% - 0.3% (w/w)) in 0.9% Sodium Chloride for injection.
Study: NCT04754009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Sensitive Yoga + TAU
Description: Trauma-Sensitive Yoga is a movement-based approach that are used to integrate both mind and body, and promote body awareness and acceptance for those who have been exposed to traumatic events and currently experience trauma symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chen Style Tai Chi + TAU
Description: Chen Style Practical Method tai chi is a martial art that is used as a form of self-defense and to maintain physical health and well-being.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Consists of traditional talk therapy for mental health.
Study: NCT00943007

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stealth Station
Description: Neuronavigation based on preoperative MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoleStar N20
Description: Intraoperative MRI guided surgery
Study: NCT04780230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS active
Description: An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS sham
Description: An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.
Study: NCT01061346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 40% Fat Diet, 20% Fructose Beverage
Description: 40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% Glucose Beverage
Description: 40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% Glucose Beverage
Description: 20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein
Study: NCT03814746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizanlizumab (SEG101)
Description: Crizanlizumab was supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for infusion.~IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizanlizumab (SEG101)
Description: Crizanlizumab was supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for infusion.~IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for infusion IV.
Study: NCT05106101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-glutamine
Description: L-glutamine oral powder in 5 gram packet
Study: NCT00122382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: abatacept 10 mg/kg IV monthly, methotrexate weekly, for 24 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo IV, monthly, methotrexate weekly for 12 months followed by abatacept 10 mg/kg IV monthly, methotrexate weekly for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Oral, titrated to at least 15 mg per week not to exceed 20 mg per week administered every 28 days from Month 12 to Month 24

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Oral, titrated to at least 15 mg per week not to exceed 20 mg per week administered every 28 days from Month 12 to Month 24
Study: NCT00662649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Description: Patients self-administered fingolimod 0.5 mg capsules orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Description: Patients self-administered fingolimod 0.5 mg capsules orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Description: Patients self-administered fingolimod 0.5 mg capsules orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Description: Patients self-administered fingolimod 1.25 mg capsules orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Description: Patients self-administered fingolimod 1.25 mg capsules orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Description: Patients self-administered fingolimod 1.25 mg capsules orally once daily.
Study: NCT02485093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Septal ventricular pacing
Description: Ventricular pacing must be at least 90%, from the septum and with optimized AV delay

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VIP
Description: Ventricular pacing must be less than 10%.
Study: NCT02465398

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fracture Shoulder Arthroplasty
Description: Implantation of the Anatomical Shoulder Fracture System